Production (Stage)
Zevra Therapeutics, Inc.
ZVRA
$8.65
$0.080.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 81.36% | -79.67% | -220.49% | -674.39% | -25.76% |
| Total Depreciation and Amortization | 5.57% | 109.40% | 2,508.06% | 1,902.56% | 1,877.22% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 107.52% | 312.79% | 758.94% | 473.55% | -145.66% |
| Change in Net Operating Assets | -4,524.32% | -89.41% | -103.08% | 77.25% | -102.12% |
| Cash from Operations | 49.14% | -0.57% | -291.98% | -119.54% | -299.63% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -28.07% | -113.33% | 29.20% | -100.38% | 184.41% |
| Cash from Investing | -28.74% | -151.69% | 29.47% | -100.38% | 184.27% |
| Total Debt Issued | -- | -100.00% | -100.00% | 5,160.25% | -- |
| Total Debt Repaid | -- | 100.00% | -100.00% | -11,981.51% | -- |
| Issuance of Common Stock | 62.61% | -86.96% | 122,098.11% | 189.16% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 32.05% | -84.09% | 146.64% | 1,511.99% | 132.45% |
| Foreign Exchange rate Adjustments | -726.67% | 92.26% | -381.37% | 219.03% | -169.23% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,877.50% | -9,106.36% | 164.46% | -113.80% | 99.21% |